Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder
Sanofi SA (NASDAQ:SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile…
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Amgen’s First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
The FDA has given accelerated approval to Amgen Inc’s (NASDAQ:AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation.…
European Drug Regulator Supports Use Of Pfizer-BioNTech COVID-19 Vaccine In Adolescents: Reuters
European Medical Agency backed the use of Pfizer Inc (NYSE:PFE) – BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine for children as young as 12,…
Humanigen Files US Emergency Use Application For Lenzilumab For COVID-19
Humanigen Inc (NASDAQ:HGEN) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for lenzilumab to treat patients hospitalized…
FDA Advisory Committee Votes In Favor Of Approval Of Provention Bio’s Diabetes Med
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in favor of recommending ap
Cyclerion Therapeutics Highlights Publication Of CY6463 Preclinical Data In Frontiers In Pharmacology
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced the publication of preclinical data of CY6463 in Frontiers in Pharmacology. Cyclerion is developing CY6463, an oral, first-in-class, central nervous
Justice Department Opens Probe In Presumed lapses at Eli Lilly’s COVID-19 Drug Plant: Reuters
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (NYSE:LLY) focused on alleged manufacturing irregularities…
Biohaven’s Verdiperstat Receives FDA ‘May Proceed’ Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) (“Biohaven” or the “Company”), a biopharmaceutical company with multiple late-stage neuroscience drug…
Despite Bright Prospects, Credit Suisse Begins Thermo Fisher With Neutral Rating
Although Thermo Fisher Scientific Inc. (NYSE:TMO) seems well-positioned to generate robust organic revenue growth and healthy margin expansion…